2022 - BrainsWay

News & Events

November 28, 2022

Transforming lives with TMS

BrainsWay was featured in special report on transforming lives with TMS. The article highlights how Deep...

November 28, 2022

BrainsWay Reports Open Market Stock Purchases by Two Board Members

BURLINGTON, Mass. and JERUSALEM, November 28, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ &...

November 22, 2022

TMS: Success in Treating Resistant Depression

An in-depth explanation of TMS, the mental illnesses that it can treat, the process of receiving the...

November 16, 2022

What Is Transcranial Magnetic Stimulation (TMS) Therapy?

An overview of TMS and the different types of treatments that are FDA-cleared. Forbes Health Article

November 3, 2022

Treatment-Resistant Depression: Alternative Options for Finding Relief

An overview of treatment-resistant depression and basic questions about Deep TMS are answered. The Mercury...

November 16, 2022

BrainsWay Reports Third Quarter 2022 Financial Results and Operational Highlights

Conference call to be held today, November 16, 2022, at 8:30 AM ET                       ...

November 3, 2022

BrainsWay Announces Private Insurance Coverage from Premera Blue Cross for the Treatment of OCD Utilizing Deep TMS™

Reflects Broader Trends Significantly Increasing Access to Deep TMS for OCD and Depression Patients BURLINGTON,...

November 2, 2022

BrainsWay to Report Third Quarter Financial Results on November 16, 2022

BURLINGTON, Mass. and JERUSALEM, Nov. 02, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

November 1, 2022

BrainsWay Appoints Dr. Colleen A. Hanlon as Vice President of Medical Affairs

Dr. Hanlon has Served as a Leader in Brain Stimulation Research for Nearly 20 Years BURLINGTON, Mass....

October 18, 2022

Georgia woman finds breakthrough for crippling depression, anxiety

Patient in Atlanta, GA who struggled with crippling depression and anxiety details her story and how...

October 14, 2022

Benchtop Bios Podcast, Episode #58: Deep TMS™ Technology

Podcast with Dr. Christopher von Jako, PhD, CEO of BrainsWay discussing BrainsWay’s Deep Transcranial...

October 6, 2022

rTMS vs. dTMS Therapy – Here are the Key Differences

Various insights into the differences between TMS treatments with Figure-8 Coils versus Deep TMS H-Coils,...

October 12, 2022

BrainsWay Launches Social Media Sweepstakes in Observance of Depression Awareness Month

The sweepstakes aims to raise awareness of Deep TMS™ as a treatment option for mental health disorders...

October 11, 2022

BrainsWay and NOCD Launch Collaboration to Increase Awareness of OCD Treatments

BURLINGTON, Mass. and JERUSALEM, Oct. 11, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

September 20, 2022

BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley

BURLINGTON, Mass. and JERUSALEM, Sept. 20, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

September 16, 2022

Cigna extends coverage for Brainsway’s brain stimulation device to treat OCD

Policy change by Cigna to now begin covering Deep TMS for the treatment of obsessive-compulsive disorder,...

September 14, 2022

BrainsWay Announces Private Insurance Coverage from Cigna Corporation for OCD Treatment

Cigna® Issues Favorable Policy for Deep TMS to Address Medication-Resistant Obsessive-Compulsive Disorder BURLINGTON,...

August 31, 2022

BrainsWay to Present at the H.C. Wainwright Annual Global Investment Conference

BURLINGTON, Mass. and JERUSALEM, August 31, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...